After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
Stocks Info
As a NASDAQ listed company, RARE falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Ultragenyx Pharmaceutical Inc is $3.18B. A total of 2.02 million shares were traded on the day, compared to an average of 792.23K shares.
In the most recent transaction, Horn Howard sold 1,785 shares of RARE for 40.40 per share on Mar 06 ’25. After the transaction, the Chief Financial Officer now owns 106,169 company shares. In a previous transaction on Mar 03 ’25, Kassberg Thomas Richard sold 6,028 shares at 42.10 per share. RARE shares that CBO & EVP owns now total 265,238.
Among the insiders who sold shares, Parschauer Karah Herdman disposed of 12,846 shares on Mar 03 ’25 at a per-share price of $42.10. This resulted in the EVP and Chief Legal Officer holding 75,287 shares of RARE after the transaction. In another insider transaction, Crombez Eric sold 8,945 shares at $42.10 per share on Mar 03 ’25. Company shares held by the EVP and Chief Medical Officer now total 71,922.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, RARE has a high of $60.37 and a low of $30.15.
As of this writing, RARE has an earnings estimate of -$1.64 per share for the current quarter. EPS was calculated based on a consensus of 9.0 estimates, with a high estimate of -$1.18 per share and a lower estimate of -$2.41.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. RARE’s latest balance sheet shows that the firm has $740.20M in Cash & Short Term Investments as of fiscal 2021. There were $41.97M in debt and $181.37M in liabilities at the time. Its Book Value Per Share was $2.76, while its Total Shareholder’s Equity was $922.56M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RARE is Buy with a score of 4.84.
